Chimeric Therapeutics Ltd (ASX:CHM) has exercised its exclusive option for the CORE-NK platform from Case Western Reserve University (CWRU).
The move will allow the clinical-stage cell therapy company to proceed with negotiations for an exclusive licence.
Chimeric has had six months to exercise this option, provided it met certain milestones in accordance with an agreed development plan.
The Clinically validated, Off the shelf, Robust, Enhanced Natural Killer (CORE-NK) cell platform technology provides an excellent foundation for accelerated development of multiple next generation NK and CAR-NK products.
In March 2022, Chimeric delivered positive final results from a Phase 1 trial of the platform conducted in blood cancers and solid tumours.
Chimeric expects to use the CORE-NK platform while leveraging its existing portfolio of CARs to pursue new clinical trials in blood cancers and solid tumours beginning in 2023.
About Chimeric
Chimeric’s team of cell therapy pioneers and experts is focused on the discovery, development and commercialisation of innovative and promising cell therapies. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours.
CHM 1101 is being studied in a phase 1 clinical trial in recurrent/progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.
CHM 2101 (CDH17 CAR T) is a novel, third-generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.
CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours.
From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.
Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.